Key Takeaways Starting dose: 2mg once weekly for the first 4 weeks to assess tolerance Titration schedule: Increase every 4 weeks: 2mg 4mg 8mg 12mg (max) Half-life: Approximately 6 days, reaching steady state in 4-5 weeks Injection frequency: Once weekly on the same day each week Microdosing option: Some users split doses for improved tolerability Investigational Drug: Retatrutide is NOT FDA-approved and is currently only available through clinical trials
For patients first prescribed an ADM in September 2025, 72.5% filled a GLP-1 RA within 60 days
Many patients begin to notice a reduction in cravings and hunger within the first few weeks, which helps them to maintain a healthy eating plan
Is it the decreased inflammation from a significant weight loss
The provider reviews the patients health, weight history, and other therapies
We, who are endocrinologists, cardiologists, and nephrologists, know well the efficacy of GLP-1 receptor agonist (GLP-1 RA) therapy in weight loss and improving cardiovascular diseases risk factors